Optimising Arthritis Strategies in Elderly patients (≥70 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference
Aalborg University Hospital, Aalborg University Hospital
Sponsor type
Hospital/Clinic/Other health care facility, Hospital/Clinic/Other health care facility
Therapeutic area
Musculoskeletal Diseases
Decision date
06/07/2026
Enrollment target
180
Sites
Denmark
Condition studied
Rheumatoid arthritis
Investigational medicinal product(s)
Jyseleca 200 mg film-coated tabletsOlumiant 4 mg film-coated tabletsINFLIXIMABCERTOLIZUMAB PEGOLHYDROXYCHLOROQUINERINVOQ 15 mg prolonged-release tabletsADALIMUMABSULFASALAZINESARILUMABRoActemra 162 mg solution for injection in pre-filled syringe.METHOTREXATEGOLIMUMABORENCIA 250 mg powder for concentrate for solution for infusionPrednisolone 5mg Soluble TabletsXELJANZ 5 mg film-coated tabletsMETHOTREXATELEFLUNOMIDEETANERCEPTRoActemra 20 mg/mL concentrate for solution for infusionORENCIA 125 mg solution for injection in pre-filled syringe
Eligibility
Age group
65+ years
Sex
Female, Male
Primary endpoint
24 months
Endpoint detail
Year 5
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.